Before you sell to, join or invest in Olema Pharmaceuticals, Inc.
MentionFox check on Olema Pharmaceuticals, Inc.: only 2 sources on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/olema-pharmaceuticals-inc-form-d-24000001
Check Olema Pharmaceuticals, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Olema Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2024-12-12.
Olema Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 12, 2024. The filing reports $250M sold. Its industry group is Pharmaceuticals. It names Sean Bohen, M.D., Ph.D. (Executive Officer, Director), David Myles, Ph.D. (Executive Officer), Shane Kovacs (Executive Officer) (SEC Form D, December 12, 2024).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Olema Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-12-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Olema Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Olema Pharmaceuticals, Inc., from the filings we hold.
J.P. Morgan Securities LLC received sales compensation on this raise and on 123 other raises we hold, nearest in date first:
Goldman Sachs & Co. LLC received sales compensation on this raise and on 90 other raises we hold, nearest in date first:
Get an email when Olema Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Olema Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Olema Pharmaceuticals, Inc. →Get the full cited report on Olema Pharmaceuticals, Inc.
What the filing shows about Olema Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Olema Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Olema Pharmaceuticals, Inc.'s address as 780 Brannan Street, San Francisco, CA 94103.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Olema Pharmaceuticals, Inc. See pricing
Olema Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1750284) and has filed since 2023-09-14. 2 filings are on record, the latest on 2024-12-12.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Olema Pharmaceuticals, Inc.'s Form D of 2024-12-12 names Sean Bohen, M.D., Ph.D., David Myles, Ph.D., Shane Kovacs and 10 more as its officers, directors or promoters.
Its new offerings report $380M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Sean Bohen, M.D., Ph.D. is named as Executive Officer and Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
David Myles, Ph.D. is named as Executive Officer on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Shane Kovacs is named as Executive Officer on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Naseem Zojwalla, M.D. is named as Executive Officer on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Yi Larson is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Andrew Rappaport is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Cynthia Butitta is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Cyrus Harmon, Ph.D. is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Sandra Horning, M.D. is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Gorjan Hrustanovic, Ph.D. is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Graham Walmsley, M.D., Ph.D. is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Ian Clark is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
Scott Garland is named as Director on the Form D that Olema Pharmaceuticals, Inc. filed with the SEC on 12 December 2024, one of 13 people that filing names.
13 people named on the filing — 4 holding an executive role and 9 as directors only.
Named as of the 2024-12-12 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 13 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Olema Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Olema Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Olema Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Olema Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Olema Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Olema Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/olema-pharmaceuticals-inc-form-d-24000001